Harvard spinout kicks off 2021 with a crossover round and sights set on the clinic

Nicole DeFeudis

Editor

Several months after striking an alliance with Novartis, TCR therapy-focused TScan Therapeutics has reeled in a crossover round that should hold it over for the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Harvard spinout kicks off 2021 with a crossover round and sights set on the clinic

Nicole DeFeudis

Editor

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Har­vard spin­out kicks off 2021 with a crossover round and sights set on the clin­ic

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Harvard spinout kicks off 2021 with a crossover round and sights set on the clinic

Applied Therapeutics' rare disease drug gets a CRL

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Updated: Roche buys out CAR-T partner Poseida for $1B upfront